TNF拮抗剂治疗难治性溃疡性直肠炎的疗效
这项法国和比利时的全国性回顾性队列研究纳入104例难治性活动性溃疡性直肠炎(UP)患者,接受至少一次抗TNF治疗。77%患者获得临床应答,50%达到临床缓解,60%内镜评估者实现黏膜愈合。1年和2年持续临床缓解累积概率分别为87.6%±3.4%和74.7%±4.8%。
要点
- 抗TNF治疗难治性UP:77%临床应答,50%临床缓解
- 随访内镜评估者中60%达到黏膜愈合
- 肠外表现及局部激素或5-ASA治疗与未缓解相关
核心结论
- 在104例难治性UP的回顾性研究中,抗TNF治疗使50%患者达到临床缓解,60%内镜评估者达到黏膜愈合,约三分之二患者在2年时仍在接受抗TNF治疗。
研究设计与样本
- 法国15个中心及比利时1个中心的全国性回顾性队列研究(GETAID队列),纳入104例连续的活动性UP且常规治疗难治的患者,2006年10月至2017年2月接受至少1次抗TNF(英夫利西单抗、阿达木单抗、戈利木单抗)治疗,中位随访24个月(IQR 13-51个月)。
主要发现
- 总体80例(77%)患者对抗TNF治疗有临床应答,52例(50%)达到临床缓解。
- 肠外表现(OR 0.24;95%CI 0.08-0.7)、正在使用局部激素(OR 0.14;95%CI 0.03-0.73)和正在使用局部5-氨基水杨酸(OR 0.21;95%CI 0.07-0.62)与未达到临床缓解显著相关。
- 随访期间接受内镜评估的63例患者中38例(60%)达到黏膜愈合。
- 总体人群(n=104)持续临床缓解的累积概率为1年87.6%±3.4%、2年74.7%±4.8%。
关键数值与推荐
- 临床应答定义为UC相关症状显著改善,临床缓解定义为UC相关症状完全消失,均由治疗医生判定。
- 主要结局为UP对抗TNF治疗的临床应答。
- 约三分之二的患者在2年时仍在接受抗TNF治疗。
临床怎么用
- 对于常规治疗难治的溃疡性直肠炎患者,抗TNF治疗可使约半数达到临床缓解、约六成内镜评估者达到黏膜愈合。
- 合并肠外表现、正在使用局部激素或局部5-氨基水杨酸的患者达到临床缓解的可能性较低。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is a challenge to manage patients with ulcerative proctitis (UP) refractory to standard therapy. We investigated the effectiveness of tumor necrosis factor (TNF) antagonists in a large cohort of patients with refractory UP. METHODS: We conducted a nationwide retrospective cohort study of 104 consecutive patients with active UP refractory to conventional therapies, treated at 1 of 15 centers in France or 1 center in Belgium (the GETAID cohort). Patients received at least 1 injection of anti-TNF (infliximab, adalimumab, golimumab) from October 2006 through February 2017. Clinical response was defined as significant improvement in UC-related symptoms, and remission as complete disappearance of UC-related symptoms, each determined by treating physicians. We collected demographic, clinical, and treatment data. The median duration of follow-up was 24 months (interquartile range, 13-51 months). The primary outcome was clinical response of UP to anti-TNF treatment. RESULTS: Overall, 80 patients (77%) had a clinical response to anti-TNF therapy and 52 patients (50%) achieved clinical remission. Extra-intestinal manifestations (odds ratio OR, 0.24; 95% CI, 0.08-0.7), ongoing treatment with topical steroids (OR, 0.14; 95% CI, 0.03-0.73), and ongoing treatment with topical 5-aminosalycilates (OR, 0.21; 95% CI, 0.07-0.62) were significantly associated with the absence of clinical remission. Sixty percent (38/63) of the patients who had endoscopic assessment during follow up had mucosal healing. Among the overall population (n = 104), the cumulative probabilities of sustained clinical remission were 87.6% ± 3.4% at 1 year and 74.7% ± 4.8% at 2 years. CONCLUSIONS: In a retrospective study of 104 patients with refractory UP, anti-TNF therapy induced clinical remission in 50% and mucosal healing in 60%. About two thirds of the patients were still receiving anti-TNF therapy at 2 years.
引用
- Pineton de Chambrun G, Amiot A, Bouguen G, et al. Efficacy of Tumor Necrosis Factor Antagonist Treatment in Patients With Refractory Ulcerative Proctitis. Clin Gastroenterol Hepatol. 2019. PMID: 31202984. doi:10.1016/j.cgh.2019.05.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。